These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23498306)

  • 1. A 6-week randomized controlled trial with 4-week follow-up of acupuncture combined with paroxetine in patients with major depressive disorder.
    Qu SS; Huang Y; Zhang ZJ; Chen JQ; Lin RY; Wang CQ; Li GL; Wong HK; Zhao CH; Pan JY; Guo SC; Zhang YC
    J Psychiatr Res; 2013 Jun; 47(6):726-32. PubMed ID: 23498306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manual or electroacupuncture as an add-on therapy to SSRIs for depression: A randomized controlled trial.
    Zhao B; Li Z; Wang Y; Ma X; Wang X; Wang X; Liu J; Huang Y; Zhang J; Li L; Hu X; Jiang J; Qu S; Chai Q; Song M; Yang X; Bao T; Fei Y
    J Psychiatr Res; 2019 Jul; 114():24-33. PubMed ID: 31015098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can acupuncture combined with SSRIs improve clinical symptoms and quality of life in patients with depression? Secondary outcomes of a pragmatic randomized controlled trial.
    Zhao B; Li Z; Wang Y; Ma X; Wang X; Wang X; Liang Y; Yang X; Sun Y; Song M; Guo T; Bao T; Fei Y
    Complement Ther Med; 2019 Aug; 45():295-302. PubMed ID: 31331577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
    J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor analysis of electroacupuncture and selective serotonin reuptake inhibitors for major depressive disorder: an 8-week controlled clinical trial.
    Yang X; Gong W; Ma X; Wang S; Wang X; Guo T; Guo Z; Sun Y; Li J; Zhao B; Tu Y
    Acupunct Med; 2020 Feb; 38(1):45-52. PubMed ID: 31544488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personality change during depression treatment: a placebo-controlled trial.
    Tang TZ; DeRubeis RJ; Hollon SD; Amsterdam J; Shelton R; Schalet B
    Arch Gen Psychiatry; 2009 Dec; 66(12):1322-30. PubMed ID: 19996037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
    Yu YM; Gao KR; Yu H; Shen YF; Li HF
    J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Cui X; Calabrese JR; Gao K;
    J Clin Psychopharmacol; 2011 Oct; 31(5):638-42. PubMed ID: 21869688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on the mechanisms of acupuncture combined with paroxetine in the treatment of mild to moderate depression based on DNA methylation analysis.
    Dilinuer Abulikemu ; Wang Y; Zeng FC; Huang YW; Zhang AJ; Hu ZH
    Zhen Ci Yan Jiu; 2024 Jul; 49(7):751-759. PubMed ID: 39020494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
    Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
    J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional value of auricular intradermal acupuncture alongside selective serotonin reuptake inhibitors: a single-blinded, randomized, sham-controlled preliminary clinical study.
    Wang H; Liu XR; Wu XJ; He TZ; Miao D; Jiang JF; Qiao HF; Yeung WF; Sun ZL
    Acupunct Med; 2021 Dec; 39(6):596-602. PubMed ID: 33657871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
    Ball WA; Snavely DB; Hargreaves RJ; Szegedi A; Lines C; Reines SA
    Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
    Perry EB; Berman RM; Sanacora G; Anand A; Lynch-Colonese K; Charney DS
    J Clin Psychiatry; 2004 Feb; 65(2):238-43. PubMed ID: 15003079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
    Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical observation on treatment of depression by electro-acupuncture combined with Paroxetine.
    Zhang GJ; Shi ZY; Liu S; Gong SH; Liu JQ; Liu JS
    Chin J Integr Med; 2007 Sep; 13(3):228-30. PubMed ID: 17898957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and Korea.
    Higuchi T; Hong JP; Jung HY; Watanabe Y; Kunitomi T; Kamijima K
    Psychiatry Clin Neurosci; 2011 Dec; 65(7):655-63. PubMed ID: 21895859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.